Pulse Shortwave Therapy in Cervical Osteoarthritis
Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
The ActiPatch is an FDA cleared pain therapy device that uses pulsed shortwaves to interrupt
pain signals at the nerve. 200 patients will be randomized and divided into an ActiPatch
treatment group and comparison analgesic drug therapy group . Subjects will be assessed with
the Neck Disability Index (NDI) at baseline and at four weeks and VAS scores will be recorded
in order to determine the efficacy of the ActiPatch device compared to Etoricoxib. Cervical
osteoarthritis causes chronic neck pain which could potentially be alleviated by the
ActiPatch without the use of medication.